Position statement on radiopharmaceutical production for clinical trials

G. Bormans, A. Buck, A. Chiti, M. Cooper, J. Croasdale, M. Desruet, V. Kumar, Y. Liu, I. Penuelas, C. Rossetti, R. Schiavo, S. W. Schwarz, A. D. Windhorst

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this survey, the application is still far from being completed due to national restrictions that are conflicting with the content of the above EU regulation. Although the nuclear medicine centers are obliged to be compliant with national regulatory, national authorities have to be required to work towards full application of the regulation. On the other hand, an update of 536/2014 that includes therapeutic radiopharmaceuticals would also be beneficial to a rational and safe advance of nuclear medicine.

Original languageEnglish
Article number12
JournalEJNMMI Radiopharmacy and Chemistry
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2017

Keywords

  • Clinical trials
  • Radiopharmaceuticals
  • Regulatory

Fingerprint

Dive into the research topics of 'Position statement on radiopharmaceutical production for clinical trials'. Together they form a unique fingerprint.

Cite this